{"id":"34a8965e-4329-4af7-9b7c-778b9b46d188","modelId":"c07d8e9a-8799-451a-8190-79a35e1ef3a6","versionId":null,"locationId":"38da4875-0208-41f5-aacb-c5e5d30c372a","operatorId":"06e82f4d-e2d5-4a09-a089-c752f2f22056","ownerId":null,"slug":"endoquest-paradigm-trial","status":"pilot","firstSeen":null,"statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":false,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":"maker_operated","sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"unreviewed","sources":[{"url":"https://www.globenewswire.com/news-release/2025/05/15/3082092/0/en/First-Procedures-Completed-with-EndoQuest-s-Endoluminal-Surgical-System-in-PARADIGM-Trial.html","title":"First Procedures Completed with EndoQuest's Endoluminal Surgical System in PARADIGM Trial","sourceName":"GlobeNewswire (EndoQuest Robotics)","publishedAt":"2025-05-15"}],"notes":null,"keyFacts":[{"label":"Trial","value":"PARADIGM Trial — FDA-approved final stage (Jan 2026)"},{"label":"Sites","value":"5 US centers: Brigham & Women's (Boston), Mayo Clinic, Houston, + 2 more"},{"label":"Enrollment","value":"50 patients, colorectal surgery"},{"label":"Status","value":"Pilot — FDA final stage approval"},{"label":"Source","value":"MassDevice, MedTech Dive, BusinessWire"}],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-07-22T21:39:27.166Z","updatedAt":"2026-07-23T03:22:39.299Z","model":{"id":"c07d8e9a-8799-451a-8190-79a35e1ef3a6","companyId":"06e82f4d-e2d5-4a09-a089-c752f2f22056","modelName":"Endoluminal Robotic Surgical System","slug":"endoquest-endoluminal","description":null,"formFactor":"surgical","industryVertical":null,"environment":null,"maturityStage":"pilot","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"unreviewed","sources":[],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[],"createdAt":"2026-07-22T21:39:25.626Z","updatedAt":"2026-07-22T21:39:25.626Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"06e82f4d-e2d5-4a09-a089-c752f2f22056","name":"EndoQuest Robotics","slug":"endoquest","description":"Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.","status":null,"founded":null,"hq":"Houston, TX","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.massdevice.com/endoquest-gets-fda-green-light-to-initiate-final-stage-of-surgical-robot-trial/","title":"EndoQuest FDA green light PARADIGM","sourceName":"MassDevice","dateAccessed":"2026-07-22"},{"url":"https://finance.yahoo.com/news/endoquest-robotics-secures-series-d-120000732.html","title":"EndoQuest Series D-2 Funding","sourceName":"Yahoo Finance/GlobeNewswire","dateAccessed":"2026-07-22"},{"url":"https://www.businesswire.com/news/home/20260112765182/en/EndoQuest-to-Bring-AI-Powered-Vision-and-Precision-to-Endoluminal-Robotic-Surgery-with-NVIDIA-IGX-Thor","title":"EndoQuest NVIDIA IGX Thor","sourceName":"BusinessWire","dateAccessed":"2026-07-22"}],"keyFacts":[{"label":"Product","value":"Endoluminal Surgical (ELS) System — flexible endoluminal robot"},{"label":"Trial","value":"PARADIGM — FDA IDE, 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA)"},{"label":"FDA Status","value":"Final stage approved (Jan 2026). First robotic ESD by gastroenterologist (Oct 2025)."},{"label":"Total Funding","value":"$176M (Series D-2, Crescent Enterprises + Dr. Fred Moll co-led)"},{"label":"Partnership","value":"NVIDIA IGX Thor integration for AI-powered vision"},{"label":"CEO","value":"Eduardo Fonseca"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-22T21:32:37.672Z","updatedAt":"2026-07-22T23:21:51.050Z"}},"version":null,"location":{"id":"38da4875-0208-41f5-aacb-c5e5d30c372a","name":"Dallas-Houston Corridor, Texas, USA","slug":"dallas-houston-texas-usa","kind":"metro","parentLocationId":"aa8b9c05-c836-4021-801f-59801970401e","region":null,"lat":30.5,"lng":-96,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-07-07T20:24:25.599Z","updatedAt":"2026-07-15T14:31:39.415Z"},"operator":{"id":"06e82f4d-e2d5-4a09-a089-c752f2f22056","name":"EndoQuest Robotics","slug":"endoquest","description":"Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.","status":null,"founded":null,"hq":"Houston, TX","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.massdevice.com/endoquest-gets-fda-green-light-to-initiate-final-stage-of-surgical-robot-trial/","title":"EndoQuest FDA green light PARADIGM","sourceName":"MassDevice","dateAccessed":"2026-07-22"},{"url":"https://finance.yahoo.com/news/endoquest-robotics-secures-series-d-120000732.html","title":"EndoQuest Series D-2 Funding","sourceName":"Yahoo Finance/GlobeNewswire","dateAccessed":"2026-07-22"},{"url":"https://www.businesswire.com/news/home/20260112765182/en/EndoQuest-to-Bring-AI-Powered-Vision-and-Precision-to-Endoluminal-Robotic-Surgery-with-NVIDIA-IGX-Thor","title":"EndoQuest NVIDIA IGX Thor","sourceName":"BusinessWire","dateAccessed":"2026-07-22"}],"keyFacts":[{"label":"Product","value":"Endoluminal Surgical (ELS) System — flexible endoluminal robot"},{"label":"Trial","value":"PARADIGM — FDA IDE, 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA)"},{"label":"FDA Status","value":"Final stage approved (Jan 2026). First robotic ESD by gastroenterologist (Oct 2025)."},{"label":"Total Funding","value":"$176M (Series D-2, Crescent Enterprises + Dr. Fred Moll co-led)"},{"label":"Partnership","value":"NVIDIA IGX Thor integration for AI-powered vision"},{"label":"CEO","value":"Eduardo Fonseca"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-22T21:32:37.672Z","updatedAt":"2026-07-22T23:21:51.050Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/endoquest-paradigm-trial","url":"https://registry.deploy.report/deployments/endoquest-paradigm-trial","name":"Endoluminal Robotic Surgical System at Dallas-Houston Corridor, Texas, USA","identifier":"34a8965e-4329-4af7-9b7c-778b9b46d188","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/dallas-houston-texas-usa","name":"Dallas-Houston Corridor, Texas, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/endoquest","name":"EndoQuest Robotics"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/endoquest-endoluminal","name":"Endoluminal Robotic Surgical System"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"unreviewed","maturity_stage":"pilot","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}